Macrogen, Inc (038290) Fair Value & Analysis

Healthcare · KR · Market cap 121B KRW

Below-average quality, and screening another 64% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (5,571 KRW). The favourable scenario is already priced in.
• Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range 10,700 KRW – 36,122 KRW · fair‑value band 3,342 KRW – 5,571 KRW · the 12,320 KRW price screens above the 4,457 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Macrogen, Inc (038290) currently trades at 12,320 KRW, while our model-based Fair Value estimate is 4,457 KRW, implying the stock looks roughly 63.8% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Macrogen, Inc generated revenue of 138B KRW at a net margin of 1.6%. Revenue grew 24.9% year over year. Net debt stands at 42.4B KRW. Fundamentals as of Jul 22, 2026

Our scenario range runs from 3,342 KRW (bear case) to 5,571 KRW (bull case); at 12,320 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 41% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -13% fair-value upside, at -64%, 038290 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based (10,514 KRW) versus Earnings-Based (2,180 KRW). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and …

Full company description

Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing services, as well as animal/plant identification, PCR optimization/amplification, pyrosequencing, NGS validation, multi locus sequence typing analysis, sanger sequencing, primer walking, and cloning services. The company also provides fragment analysis services; clinical diagnostic; personal genome analysis; genetic testing services for research purposes, such as messenger RNA, microRNA, single nucleotide polymorphism, comparative genome hybridization, and DNA methylation; oligo and gene synthesis; and clustered regularly interspaced short palindromic repeats design and synthesis material, gRNA synthesis, validated gRNA, and gRNA plasmid services. In addition, it offers genetically engineered mice for use in biological and medical research to identify the functions of human genes; transgenic mouse in which a specific gene has been inserted to study the function of the gene; and GEM-related services, including mass reproduction, microinjection, mouse line recovery, embryo freezing and reproduction, and KO/TG mouse maintenance. Further, the company provides covid-19 test kit under the Axen name, as well as operates smart mobile lab for covid-19 testing. Additionally, it offers iD4U genetic testing services for kinship and personal identification; and myPETGENE genetic testing service for pets. Macrogen, Inc. was founded in 1997 and is headquartered in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Macrogen, Inc reported revenue of 195B KRW in FY2025 versus 129B KRW in FY2021, a compound +10.9%/yr. Reported net income was 2.0B KRW in FY2025, compounding +16.2%/yr from FY2021.

038290 screens 64% overvalued. Compare with MEDIPOST Co →

Peer Group

Health Care · 2228 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.